UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Investigational new drugs, 2013-08, Vol.31 (4), p.833-844

2013

Volltextzugriff (PDF)

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

Investigational new drugs, 2018-08, Vol.36 (4), p.536-544

2018

Volltextzugriff (PDF)

Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever

The Journal of infectious diseases, 2007-11, Vol.196 (Supplement-2), p.S390-S399

2007

Volltextzugriff (PDF)

Troponin-I as a prognosticator of mortality in severe sepsis patients

Journal of critical care, 2010-06, Vol.25 (2), p.270-275

2010

Volltextzugriff (PDF)

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Critical care (London, England), 2004-04, Vol.8 (2), p.R82-R90, Article R82

2004

Volltextzugriff (PDF)

Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis

Chest, 2001-09, Vol.120 (3), p.915-922

2001

Volltextzugriff (PDF)

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

Critical care medicine, 2001-11, Vol.29 (11), p.2051-2059

2001

Volltextzugriff (PDF)

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

Critical care medicine, 2000-07, Vol.28 (7), p.2209-2216

2000

Volltextzugriff (PDF)

Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis

Thrombosis and haemostasis, 2003-10, Vol.90 (4), p.642-653

2003

Volltextzugriff (PDF)

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)

Critical care (London, England), 2005-01, Vol.9 Suppl 4 (Suppl 4), p.S38-S45

2005

Volltextzugriff (PDF)

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

Clinical cancer research, 2014-12, Vol.20 (23), p.6059-6070

2014

Volltextzugriff (PDF)

Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Clinical cancer research, 2013-10, Vol.19 (20), p.5699-5710

2013

Volltextzugriff (PDF)

Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling

Critical care medicine, 2004-05, Vol.32 (5 Suppl), p.S302-S308

2004

Volltextzugriff (PDF)

Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies

Critical care (London, England), 2005-08, Vol.9 (4), p.R331-R343, Article R331

2005

Volltextzugriff (PDF)

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Investigational new drugs, 2017-06, Vol.35 (3), p.334-344

2017

Volltextzugriff (PDF)

Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents

Journal of antimicrobial chemotherapy, 2007-06, Vol.59 (6), p.1177-1181

2007

Volltextzugriff (PDF)

Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest : Implication of the protein C anticoagulant pathway

Journal of the American College of Cardiology, 2005-07, Vol.46 (1), p.21-28

2005

Volltextzugriff (PDF)

Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis

Critical care medicine, 2002-05, Vol.30 (5 Suppl), p.S318-S324

2002

Volltextzugriff (PDF)

Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia

Blood, 2003-11, Vol.102 (9), p.3085-3092

2003

Volltextzugriff (PDF)

Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C

Critical care medicine, 2004-05, Vol.32 (5 Suppl), p.S239-S246

2004

Volltextzugriff (PDF)

Activated protein C versus protein C in severe sepsis

Critical care medicine, 2001-07, Vol.29 (7 Suppl 1), p.S69-S74

2001

Volltextzugriff (PDF)

Systemic host inflammatory and coagulation response in the Dengue virus primo-infection

Cytokine (Philadelphia, Pa.), 2004-09, Vol.27 (6), p.173-179

2004

Volltextzugriff (PDF)

Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis

Critical care medicine, 2004-05, Vol.32 (5 Suppl), p.S194-S201

2004

Volltextzugriff (PDF)

Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)

Clinical infectious diseases, 2003-07, Vol.37 (1), p.50-58

2003

Volltextzugriff (PDF)

Coagulopathy After Successful Cardiopulmonary Resuscitation Following Cardiac Arrest

Journal of the American College of Cardiology, 2005-07, Vol.46 (1), p.21-28

2005

Volltextzugriff (PDF)

1 – 25 von 298

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(276)
Mit Volltextzugriff
(265)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(298)

Erscheinungsjahr

n.n

Thema

Science & Technology
(184)
Life Sciences & Biomedicine
(158)
Humans
(125)
Animals
(68)
Biological And Medical Sciences
(47)
Male
(46)
Female
(41)
Mice
(40)
Medical Sciences
(31)
Middle Aged
(26)
Adult
(24)
Fundamental And Applied Biological Sciences. Psychology
(22)
Proteins
(22)
Science & Technology - Other Topics
(22)
Immunology
(20)
General & Internal Medicine
(19)
Multidisciplinary Sciences
(19)
Oncology
(19)
Pharmacology & Pharmacy
(19)
Critical Care Medicine
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever

Troponin-I as a prognosticator of mortality in severe sepsis patients

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling

Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents

Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest : Implication of the protein C anticoagulant pathway

Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis

Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia

Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C

Activated protein C versus protein C in severe sepsis

Systemic host inflammatory and coagulation response in the Dengue virus primo-infection

Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis

Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)

Coagulopathy After Successful Cardiopulmonary Resuscitation Following Cardiac Arrest

Suchergebnisse filtern